THOUSAND OAKS, Calif., Sept. 24, 2024 /PRNewswire/ -- Amgen (AMGN) today announced TEPEZZA ® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...

LOS ANGELES, CA, UNITED STATES, January 22, 2026 / EINPresswire.com / — Renowned physician Dr. Raymond Douglas will be featured in an upcoming local segment of The Balancing Act ®, a nationally ...

Please provide your email address to receive an email when new articles are posted on . Thyroid eye disease treatments have evolved significantly in recent years. Work is still needed to find durable, ...

Please provide your email address to receive an email when new articles are posted on . Until recently, patients with active thyroid eye disease had limited options for treatment of their condition ...

(RTTNews) - Amgen (AMGN) said that Japan's Ministry of Health, Labour and Welfare approved TEPEZZA (Teprotumumab) for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease ...

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of ...

Xeris Biopharma Holdings has entered a licensing agreement with pharmaceutical giant Amgen to develop a new formulation of Tepezza, one of the drugs Amgen picked up in its $27.8 billion acquisition of ...

During the Q&A portion of Amgen’s quarterly conference call Thursday, eight of the first nine questions were about the company’s investigational efforts in obesity. The buzz about Amgen’s pipeline—and ...